Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Cancer · 15.05.2023 · 129 (10) · 1547-1556
DOI: 10.1002/cncr.34701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 22.02.2023. Verfasst von Vidya Puthenpura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Hematology and Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Ethnicity, Minority Groups. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The increasing number of childhood cancer survivors necessitates continued follow‐up to monitor for long‐term complications. Inequities in loss to follow‐up for patients enrolled on pediatric clinical trials have not been well studied.
Methods
This was a retrospective study of 21,084 patients residing in the United States enrolled on phase 2/3 and phase 3 Children's Oncology Group (COG) trials between January 1, 2000 and March 31, 2021. Rates of loss to follow‐up to COG were evaluated using log‐rank tests and multivariable Cox proportional hazards regression models with adjusted hazard ratios (HRs). Demographic characteristics included age at enrollment, race, ethnicity, and zip code level socioeconomic data.
Results
Adolescent and young adult (AYA) patients 15–39 years old at diagnosis had an increased hazard of loss to follow‐up compared to patients 0–14 years old (HR, 1.89; 95% confidence interval (CI), 1.76–2.02). In the overall cohort, non‐Hispanic Blacks were found to have an increased hazard of loss to follow‐up compared to non‐Hispanic Whites (HR, 1.56; 95% CI, 1.43–1.70). Among AYAs, the highest loss to follow‐up rates were among non‐Hispanic Blacks (69.8% ± 3.1%), patients on germ cell tumor trials (78.2% ± 9.2%), and patients living in zip codes with a median household income ≤150% of the federal poverty line at diagnosis (66.7% ± 2.4%).
Conclusions
AYAs, racial and ethnic minority patients, and those living in lower socioeconomic status areas had the highest rates of loss to follow‐up among clinical trial participants. Targeted interventions are warranted to ensure equitable follow‐up and improved assessment of long‐term outcomes. Plain Language Summary Little is known about disparities in loss to follow‐up for pediatric cancer clinical trial participants. In this study, we found that participants who were adolescents and young adults when treated, those who identified as a racial and/or ethnic minority, or those residing in areas with lower socioeconomic status at diagnosis were associated with higher rates of loss to follow‐up. As a result, the ability to assess their long‐term survival, treatment‐related health conditions, and quality of life is hindered. These findings suggest the need for targeted interventions to improve long‐term follow‐up among disadvantaged pediatric clinical trial participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Pediatric Hematology and Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Children's Oncology Group, Monrovia, California, USA.
- Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Vidya Puthenpura
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Puthenpura, V., Ji, L., Xu, X., Roth, M. E., Freyer, D. R., Frazier, A. L., Marks, A. M., & Pashankar, F. D. (2023). Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer, 129(10), 1547-1556. https://doi.org/10.1002/cncr.34701
Vancouver
Puthenpura V, Ji L, Xu X, Roth ME, Freyer DR, Frazier AL, et al. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer. 2023;129(10):1547-1556. doi:10.1002/cncr.34701
BibTeX
@article{Puthenpura2023,
author = {Puthenpura, Vidya and Ji, Lingyun and Xu, Xinxin and Roth, Michael E and Freyer, David R and Frazier, A Lindsay and Marks, Asher M and Pashankar, Farzana D},
title = {Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group},
journal = {Cancer},
year = {2023},
volume = {129},
number = {10},
pages = {1547--1556},
doi = {10.1002/cncr.34701}
}
EUVIMED